ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, supports the U.S. Food and Drug Administration’s (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab).